[{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lisinopril","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alvogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Alvogen \/ Aztiq","highestDevelopmentStatusID":"12","companyTruncated":"Alvogen \/ Aztiq"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ALMATICA PHARMA INC","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals, Inc."}]

Find Clinical Drug Pipeline Developments & Deals for Lisinopril

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.

                          Brand Name : Zestril

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 18, 2023

                          Lead Product(s) : Lisinopril

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : TWi Pharmaceuticals

                          Deal Size : $38.5 million

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.

                          Brand Name : Zestril

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 30, 2021

                          Lead Product(s) : Lisinopril

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : AZTIQ PHARMA

                          Deal Size : $350.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 19, 2020

                          Lead Product(s) : Lisinopril

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank